Projects

At BSIM Therapeutics, we are pairing cheminformatics, molecular modeling, data mining and machine learning techniques with in vitro and in vivo validation to discover potent and selective transthyretin stabilizers, holding physicochemical properties suitable for acting in multiple target organs – including the eye, the brain and the blood plasma.

AMILOTERA

Medium compete Medium xlogo qren 1024x388.png.pagespeed.ic.w5zpnf2xms Medium logo ue feder bom

AMILOTERA CENTRO-07-0202-FEDER-021622

Approved on July 11, 2011 for the reinforcement of research, technological development and innovation. Project supported through the National Strategic Reference Framework (QREN).

Start Date:

02/01/2012

End Date:

30/06/2015

Total Eligible Value:

707.006,84 €

EU Funding:

FEDER 500.000,00 €

Development and optimization of therapeutic agents against transthyretin amyloidoses

Beneficiary: consortium BSIM Therapeutics (leader) / UC / CNC


Discovery of novel inhibitors of transthyretin amyloid fibril formation. More than 100 mutations in the transthyretin (TTR) gene are linked to amyloidosis, with the V30M and V122I variants being the most common in hATTR-PN and hATTR-CM, respectively. Mutations affect not only the stability and deposition sites of the TTR protein, but also TTR’s propensity to associate with small organic molecules. Most molecules currently under test, including the EMA-approved drug, display modest levels of stabilization of the most unstable TTR variants. The AMILOTERA programmed paved the way to the discovery of three lead compound series with unprecedent pharmacological potential, displaying inhibitory activity against multiple variants of TTR.

NEUROTERA

Medium logo compete2020 02 02 Medium logo pt2020 Medium logo ue feder bom

NEUROTERA POCI-01-0247-FEDER-003431

Approved on November 23, 2016 for the reinforcement of research, technological development and innovation. Project supported by COMPETE 2020 of PT2020, through the European Regional Development Fund.

Start Date:

16/08/2016

End Date:

15/02/2019

Total Eligible Value:

1.136.307,60 €

EU Funding:

FEDER 891.220,51 €

Development of innovative drugs against ocular and cerebral co-morbidities associated to Familial Amyloid Polyneuropathy

Beneficiary: consortium BSIM Therapeutics (leader) / UC / IBMC


Targeting potent TTR amyloid inhibitors to meet multiple clinical manifestations. Loss of visual acuity, ischemic events and cerebral bleeding are today part of the clinical spectrum of TTR-FAP and its treatment is not addressed by currently known/available therapies. The NEUROTERA programme aims at exploiting a series of potent TTR amyloid inhibitors discovered throughout our AMILOTERA programme, by targeting selected drug candidates to the EYE and the BRAIN, for the treatment of the clinical manifestations linked with those organs.

TERAPI-1

Medium pocentro pt2020 Medium logo pt2020 Medium logo ue feder bom

TERAPI-1 CENTRO-01-0247-FEDER-028007

Approved on October 20, 2017 for the reinforcement of research, technological development and innovation. Project supported by CENTRO 2020 of PT2020, through the European Regional Development Fund.

Start Date:

20/05/2017

End Date:

19/05/2019

Total Eligible Value:

48.768,66 €

EU Funding:

FEDER 24.384,33 €

Intellectual property protection of new therapeutic agents (AT50) against transthyretin amyloidoses.

Beneficiary: BSIM Therapeutics


Protecting our knowledge. Securing international protection for intellectual property by means of patent law is critical to our company’s business strategy, allowing commercial exploitation of our products and future growth of the company. Having attained proof-of-principle against several disease-modifying endpoints with our best TTR stabilizers, each with licensing potential, we have shown that it is possible to develop innovative next-generation small molecule therapies against transthyretin (TTR) amyloidoses. The project CENTRO-01-0247-FEDER-028007 aim at supporting the patenting of the AT50 technology.

TERAPI-2

Medium pocentro pt2020 Medium logo pt2020 Medium logo ue feder bom

TERAPI-2 CENTRO-01-0247-FEDER-032687

Approved on October 20, 2017 for the reinforcement of research, technological development and innovation. Project supported by CENTRO 2020 of PT2020, through the European Regional Development Fund.

Start Date:

01/06/2017

End Date:

31/05/2020

Total Eligible Value:

50.000,00 €

EU Funding:

FEDER 25.000,00 €

Intellectual property protection of new therapeutic agents (AT40) against transthyretin amyloidoses

Beneficiary: BSIM Therapeutics


Protecting our knowledge. Securing international protection for intellectual property by means of patent law is critical to our company’s business strategy, allowing commercial exploitation of our products and future growth of the company. Having attained proof-of-principle against several disease-modifying endpoints with our best TTR stabilizers, each with licensing potential, we have shown that it is possible to develop innovative next-generation small molecule therapies against transthyretin (TTR) amyloidoses. The project CENTRO-01-0247-FEDER-032697 aim at supporting the patenting of the AT40 technology.

By continuing to browse the site, you expressly agree that cookies will be stored on your computer to help measure statistics of visits and improve the quality of the contents offered.Learn more